News

MolecularMatch Releases Free COVID-19 and Coronavirus Trial Tracking Tool

MolecularMatch Releases Free COVID-19 and Coronavirus Trial Tracking Tool

HOUSTON, TX, April 14, 2020 – MolecularMatch, a leading clinical informatics company, has released a free, web-based portal to help researchers, physicians and patients find clinical trials for COVID-19 and coronavirus. The portal, available at VirusTrials.com, includes over 800 clinical trials across the globe for therapies and vaccines being tested for COVID-19. Physicians and patients can use their country, state or postal code to find enrolling trials nearest to the patient. Specific patient age, symptoms, severity and comorbidities are used to help find trials best suited to that individual. In addition to trials, the portal can also be used to search for literature and publications related to COVID-19.

“The number of therapeutic cures and vaccines being tested are growing at an astounding rate,” said Eric Pulaski, CEO at MolecularMatch. “Our tools make it easier for clinicians and patients to find the help they need. Hopefully, we can help save lives by shortening the time it takes to get more patients into clinical trials and by speeding up research to find cures and vaccines.”

MolecularMatch is providing the tool as a free public service in hopes of placing thousands of patients into trials as quickly as possible and saving researchers’ valuable time. Using the company’s highly-automated, AI-based curation platform, both the clinical trials database (currently, over 800) and publications (currently, over 2,400) are being updated every 2-3 days.

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company established in 2014. The company was founded on the vision of using tumor molecular profiling and outcomes from previously-treated patients to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include molecular labs, health information systems, biopharma, second opinion and payer companies, as well cancer centers on a global basis. Visit us at molecularmatch.com or follow us on Twitter or LinkedIn.

MolecularMatch Releases Support for Coronavirus New v4.1 Adds Search Results for COVID-19 Clinical Trials and Publications

MolecularMatch Releases Support for Coronavirus

New v4.1 Adds Search Results for COVID-19 Clinical Trials and Publications

HOUSTON, TX, April 6, 2020 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions, has updated the MolecularMatch search engine with new features and content to support customers’ response to the novel coronavirus pandemic. Updates include access to hundreds of clinical trials and thousands of publications that are applicable to coronavirus and COVID-19.

With the built-in search features of the MolecularMatch search engine, users can locate the most appropriate clinical trials and publications for individual patients, including filtering clinical trials for inclusion and exclusion criteria based on patient-specific clinical details and narrowing search results to trial sites by a patent’s geographic location. Institutions can also upload private trials to the MolecularMatch database that are not yet indexed in the public registries.

“Our team has been working overtime to add support for coronavirus and COVID-19 clinical trials and publications,” said Eric Pulaski, CEO of MolecularMatch. “Although the focus of our curated content has been on oncology, the versatility of our core platform enabled us to quickly add support for new content in this area of infectious disease. We’re stepping up to the plate to do our part to support researchers, labs, healthcare providers, and others in the global fight against the novel Coronavirus pandemic.”

Version 4.1 of the company’s web-based portal (MMPortal) and REST API (MMPower) are available immediately, and all current customers have access to the new content at no additional charge. The MolecularMatch Knowledge Graph and content across the MolecularMatch knowledgebase have been enhanced with the following:

  • Added support for antiviral drugs and drug classes
  • Added virology, emergency medicine and infectious disease related journals and publications (over 2,300 publication entries)
  • Added global registry clinical trials related to coronavirus/COVID-19 (over 360 trials)
  • MolecularMatch’s clinical comprehension and ranking applied to this new data

The MolecularMatch COVID-19 database is updated every 2-3 days. The company is also exploring other ways to help battle this pandemic with new offerings to reach a wider base of users who can benefit from the MolecularMatch search engine.

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company established in 2014. The company was founded on the vision of using tumor molecular profiling and outcomes from previously-treated patients to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include molecular labs, health information systems, biopharma, second opinion and payer companies, as well as cancer centers across the globe. Visit us at molecularmatch.com or follow us on Twitter or LinkedIn.

2nd.MD Selects MolecularMatch to Help Guide Therapeutic and Clinical Trial Options for Cancer Patients

2nd.MD Selects MolecularMatch to Help Guide Therapeutic and Clinical Trial Options for Cancer Patients

HOUSTON, TX, March 24, 2020 –MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced today that it has executed an agreement to provide software licensing and support to Innovation Specialists LLC, 2nd.MD, a leading provider of virtual medical second opinions, appropriately managing risks for patients, employers, and payers. 2nd.MD oncology case managers will utilize the MolecularMatch platform to find the most appropriate drugs and clinical trials for patients based on genomics and patient-specific clinical details. The recommendations are then shared with 2nd.MD oncology specialists and the patients’ physicians.

“We have come to a point in cancer care, with genomics and precision medicine, where timely and accurate information can save lives,” said Jason Melton, the CEO at 2nd.MD. MolecularMatch CEO Eric Pulaski adds, “Our collaboration with 2nd.MD not only has the ability to save lives, but to save payers, employers and families money and time.” The two Houston-based companies have begun system integration and employee training for the growing clinical staff at 2nd.MD.

About 2nd.MD

2nd.MD offers medical certainty by connecting you with board-certified, leading specialists from across the country for an expert second opinion via video or phone within 3 to 5 days from the comfort of your own home. From the minute you reach out, 2nd.MD’s Care Team of nurses will put you at the center of your medical care by coordinating all the details. This includes, understanding your health goals, gathering all your medical records and connecting you with a doctor who specializes in your specific medical condition, so that you can focus on what matters most — getting the best care possible. No travel. No hassle. No cost. If you haven’t used 2nd.MD before, it can be life changing. In fact, 98% of people who use 2nd.MD recommend it to their friends and family.

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas- based clinical informatics SaaS company established in 2014. The company was founded on the vision of using tumor molecular profiling and outcomes from previously treated patients to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include molecular labs, health information systems, biopharma, second opinion and payer companies, as well as cancer centers on a global basis. Visit us at molecularmatch.com.

MolecularMatch Announces new SDK and Improved Drug Search

MolecularMatch Announces new SDK and Improved Drug Search

Houston – October 2, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced the release of MMPower v4, the latest update to its Clinical Decision Support platform. This new release adds expanded therapeutic guidance and a new Software Developer’s Kit (SDK) to broaden language support and speed up time-to-market for software developers writing custom applications integrating with the MolecularMatch platform.

Key new features for MolecularMatch’s expanded therapeutic guidance include:

  • Expanded pharmacology details including mechanism of action, toxicity,
    contraindication and drug metabolism
  • Regional approval status now includes EMA and HCA in addition to FDA
  • Dosage options
  • Pricing specifics

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company established in 2014. The company was founded on the vision of using tumor molecular profiling and outcomes from previously-treated patients to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals and cancer centers. Visit us at molecularmatch.com or follow us on Twitter or LinkedIn.

Scott L. Bender
MolecularMatch
+1-214-435-4498
sbender@molecularmatch.com

MolecularMatch Announces Issuance of US Patent for its Precision Medicine Service

MolecularMatch Announces Issuance of US Patent for its Precision Medicine Service

Houston – August 08, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced today that the United States Patent and Trademark Office has issued US Patent 10,360,349 covering its Precision Medicine Service for use by hospitals, pharmaceutical companies, laboratories, health information systems and the broader clinical informatics industry.

This latest patent covers the foundational technology for therapeutic guidance and clinical trial matching in MolecularMatch’s MM-Power and MM-Portal products.

“The Precision Medicine Service patent covers the process of data acquisition, curation and validation of our industry leading clinico-biological knowledge platform. It includes a state-of-the-art search engine designed to rank clinical relevance to a patient’s medical profile, providing real-time search results of treatment options inclusive of clinical trials,” said Nick Tackes, CTO at MolecularMatch. “Furthermore, our patent covers our clinical trial enrollment technology which is designed to expedite what is often a protracted process.”

“This patent is an important component as we continue to build upon strategic and technological advancements for our clinical decision support solutions,” said Eric Pulaski, President at MolecularMatch.

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company established in 2014. The company was founded on the vision of using tumor molecular profiling and outcomes from previously-treated patients to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals and cancer centers. Visit us at molecularmatch.com or follow us on Twitter or LinkedIn.

MolecularMatch appoints Eric Pulaski as President

MolecularMatch appoints Eric Pulaski as President

Pulaski joins executive team to drive product strategy and revenue growth

Houston – June 24, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced today that Eric Pulaski will serve as President for MolecularMatch.

Pulaski has over 30 years of experience across the technology and software sector. Pulaski was most recently the Founder and CEO of SmartVault Corporation, a leading SaaS provider in the online document management and secure portal space. He founded the company in 2007 and ultimately sold it to Reckon Ltd in 2016. He was the founder and CEO of BindView, where he grew that company into a leading, global Internet Security company with over $70M in revenues and 650 employees, and later sold to Symantec for over $200M. Pulaski also founded and served as CEO for several other tech companies, including RedFlag Software and Lightbulb Technology Partners.

As a serial entrepreneur, Eric’s specialties are developing and executing product strategy, building and retaining high-performing teams during high-growth and change, evangelism and communication, and managing shareholder and investor relationships.

“Eric’s experience as a seasoned entrepreneur, especially as it relates to software businesses, makes him the perfect choice in leading MolecularMatch through a very unique period for our company,” said James W. Welsh, MD, Founder at MolecularMatch. “I am confident he will spearhead strategic initiatives that will help us accelerate growth.”

Pulaski said: “MolecluarMatch is a visionary company with a vibrant culture at the forefront of innovation in the heart of the Texas Medical Center. I look forward to working closely with Jim and the leadership team to capitalize on the enormous market opportunities in front of us.”

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company founded in 2014 out of MD Anderson Cancer Center. The company was founded on the vision of using tumor molecular profiling, and outcomes from previously-treated patients, to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals and cancer centers. Visit us at molecularmatch.com